One notable example is the RENATA study, which offers valuable insights into the real-world use of palbociclib in patients with HR+/HER2− advanced breast cancer, complementing the findings from randomised controlled trials (RCTs) such as PALOMA-2 and PALOMA-3. Here, HR is linked to breast carcinoma.